Oncology
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
Latest News
Screening Identifies Familial Risk for Hereditary Breast and Ovarian Cancer in Large Health System
The number needed to test to detect one BRCA1/2-positive patient decreased from 128 to 53 for women and from 119 to 42 for men when prescreening...
From the Journals
Black Women Have a Higher Risk for Death in BC Subtypes
Researchers examined racial differences in BC survival by subtype through conducting a systematic review and meta-analysis of 18 US studies.
News from the FDA/CDC
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The FDA also approved ribociclib and the aromatase inhibitor letrozole packaged together for the same indication.
Latest News
Melanoma: Neoadjuvant Immunotherapy Provides Optimal Survival Results
Those who received combination therapy achieved higher event- and recurrence-free survival than patients who received monotherapy.
From the Journals
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
Latest News
A CRC Blood Test Is Here. What Does it Mean for Screening?
While an exciting option, the test has its pros and cons.
Commentary
Starting Mammography at Age 40 May Backfire Due to False Positives
A patient who follows the USPSTF recommendation and starts screening at age 40 has a 42% chance of having at least...
From the Journals
Fecal Immunochemical Test Performance for CRC Screening Varies Widely
Despite widespread use of FITs for CRC screening, there is limited data to help guide test selection.
From the Journals
Should Genetic Testing Be Routine for Breast Cancer?
Researchers conducted a cross-sectional study of 729 women with newly diagnosed invasive breast cancer to assess the efficacy of universal genetic...
News from the FDA/CDC
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The drug combo was the first programmed death–ligand 1 inhibitor to gain approval for subcutaneous administration.